Wyss Center Partners with BrainScape Medical to License Groundbreaking Epios® Technology
6.2.2025 09:08:00 CET | Business Wire | Press Release
The Wyss Center for Bio and Neuro Engineering is pleased to announce a strategic partnership with BrainScape Medical, a newly established company specializing in long-term brain monitoring and neurostimulation. This collaboration marks a major step in translating innovative neurotechnology into real-world clinical solutions.
The Wyss Center has granted BrainScape Medical an exclusive license for Epios®, a cutting-edge platform designed for continuous, long-term brain activity monitoring. Epios® offers a minimally invasive solution for diagnosing and treating neurological disorders, with first-in-human trials demonstrating promising results.
Transforming Neurological Care with Epios®
Epios® provides full-head subscalp EEG monitoring using minimally invasive electrodes, allowing for continuous brain activity recording. This is critical for managing conditions such as epilepsy and dementia. Uniquely, the system integrates both monitoring and neuromodulation, enabling real-time therapeutic interventions.
Dr. Erwin Böttinger, Director of the Wyss Center, stated, “We are thrilled to see Epios® progressing toward clinical application. Our partnership with BrainScape Medical reflects our commitment to advancing impactful neurotechnologies that have market impact and directly benefit patients.”
Laura Johnson, CEO of BrainScape Medical, added, “Epios® represents a significant advancement in neurotechnology. Our goal is to bring this innovative solution to patients worldwide, improving their experience managing and living with their neurological disorder through better diagnosis and treatment.”
About Wyss Center: The Wyss Center is an independent, not-for-profit organization focused on advancing neurotechnologies to improve the lives of people with neurological and mental health disorders. Based at Campus Biotech in Geneva, Switzerland, the Center develops transformative solutions in artificial intelligence, bioengineering, and neuroengineering to restore essential neural functions and deliver precision therapies. Established in 2014 with the support of Swiss entrepreneur and philanthropist Hansjörg Wyss, the Center collaborates with academic, clinical, and industry partners globally to drive innovation and maximize clinical impact.
NOTE: Epios is a registered Trademark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205481964/en/
Contacts
Wyss Center for Bio and Neuro Engineering
Aldonza Gübeli
Email: aldonza.gubeli@wysscenter.chWebsite: www.wysscenter.ch -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.wysscenter.
ch&esheet=54200150&newsitemid=20250205481964&lan=en-US&anchor=www.wysscenter.ch&
index=1&md5=7c855b3d9dabd44e3d2dde16077cec95
BrainScape Medical
Laura Johnson, CEO
Email: laura.johnson@brainscape-medical.com
Website: www.brainscape-medical.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.brainscape-
medical.com&esheet=54200150&newsitemid=20250205481964&lan=en-US&anchor=www.brain
scape-medical.com&index=2&md5=d6dc920f0f6c771023f335a08975c602
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press Release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom